CA
NZ
UK
AU
IND
US
Scholar Rock Holding Corp (NASDAQ: SRRK) announced the launch of an at-the-market (ATM) offering, aiming to sell up to $200 million in common stock. This approach allows the company to capitalize on favorable market conditions while boosting its liquidity position. The decision comes at …
This loss is greater than the previous year's $18.1 million, as the biopharmaceutical firm intensifies its efforts on several promising trials aimed at cystic fibrosis treatment. The company recorded earnings per share of $-0.60, which missed the consensus estimate of $-0.52. Such performance highlights …
Sotera Health Company (NASDAQ: SHC) delivered a strong second quarter with adjusted earnings per share of $0.26, surpassing the consensus estimate of $0.24. The company's net revenues surged 9.2% year-over-year, bolstered by performance across its business units. This strong financial footing laid the groundwork …
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported impressive financial results for the second quarter, achieving $173.9 million in net product sales from XDEMVY. This marks an increase of over 69% compared to $102.7 million in the same quarter of the previous year. This strong sales …
This represents a slight widening of losses from the previous year's figure of $0.05 per share. The company is grappling with share price declines, with shares down 7.2% year-to-date and 14.7% over the past month. Ocugen's current market capitalization stands at approximately $434 million, …
This loss marks an increase compared to the $7.4 million incurred during the same period in 2025. Despite falling short of a $0.14 consensus estimate for the quarter, the company aims to bolster investor confidence through its advancing pipeline of gene therapies. The results …
Oscar Health, Inc. has recorded a significant milestone in its financial performance, reporting an earnings per share (EPS) of $1.10 for the quarter ending June 30, vastly exceeding the $0.39 consensus estimate. The surge in profitability reflects Oscar’s strategic initiatives and recovery in the …
This change comes after the recruitment of patients in the 10 mg/kg cohort and reflects a proactive response to safety data from ongoing trials.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has reported a narrower net loss for the second quarter of 2026, posting an EPS of $-2.87 compared to a consensus estimate of $-3.73. The decrease in losses highlights potential investor confidence amid a competitive environment, suggesting that …
Precision BioSciences, Inc. (NASDAQ: DTIL) announced a second-quarter EPS of $-0.75, falling short of the $-0.67 consensus estimate, highlighting challenges in its path to profitability. This result contrasts the strong performance of the previous quarter, where the company faced an uphill battle in securing …
Please wait processing your request...